Trastuzumab Deruxtecan Approved in Japan for HER2+ Metastatic Breast Cancer – OncLive

breast cancer

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved trastuzumab deruxtecan (Enhertu) for the treatment of patients with HER2-positive unresectable or recurrent breast cancer who have had prior chemotherapy and are refractory or intolerant to standard treatments.

… to read the full story
Read More

Related Articles

Leave a Replay